Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Celltrion Pharmaceutical company has finally completed merging with its Celltrion Healthcare affiliate. This comes after the board of directors has given the “go-ahead” signal for the merger on Thursday, Dec. 28.
The unification of Celltrion and Celltrion Healthcare happened three years after the plan was first announced by the former. According to Korea Joongang Daily, the newly formed entity, following the completion of the affiliation, will then proceed to go into another merger process, this time with Celltrion Pharm. This second deal is expected to be completed sometime next year.
New Unified Entity to Enter Another Merger Deal
The new company was formed after Celltrion and Celltrion Healthcare were successfully consolidated into one entity. This will be merged with Celltrion Pharma, and the resulting new organization will have Celltrion Holdings as its largest shareholder with a 21.5% share.
In any case, it was mentioned that Celltrion’s founder and chairman, Seo Jung Jin, still has a 98.1% stake in the group’s holdings firm. As three firms are being consolidated with this succession of mergers, the company is aiming to reach KRW2 trillion won or about $9 billion in annual revenue by the year 2030.
“Celltrion was able to secure massive funds through the merger and will invest them in our new future growth engines like biosimilars, new drug development and mergers and acquisitions,” Celltrion commented.
Appointment of Three CEOs for the Merged Company
The integrated Celltrion company is set to be managed by three chief executive officers. Korea’s Alphabiz reported that the appointed executives include Ki Woo Sung, who will supervise the manufacturing and development division; Kim Hyung Ki, who will be assigned to manage the global sales unit; and Seo Jin Seok, who will become head of the business management unit.
Celltrion will start operating as a representative system for the three chiefs soon.
Photo by: Celltrion Media Center
